Information  X 
Enter a valid email address

Company Name matching 'XBiotech Inc'

Date
Time Source
Company
Announcement
11 Jul 2019 1:30 pm GNW     XBiotech Inc. Dr. Seth Forman to Chair XBiotech’s Second Phase 2 Study of Bermekimab in Atopic Dermatitis
10 Jul 2019 1:00 pm GNW     XBiotech Inc. XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board
09 Jul 2019 1:00 pm GNW     XBiotech Inc. Medical Research Council Funds Phase 2 Multi-Center Study of XBiotech’s Bermekimab in Advanced Cancer Patients
26 Jun 2019 1:30 pm GNW     XBiotech Inc. XBiotech Wins “Commercial Real Estate Award for Industrial Development” for its Headquarters in Austin, Texas
25 Jun 2019 1:45 pm GNW     XBiotech Inc. XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa
11 Jun 2019 1:00 pm GNW     XBiotech Inc. XBiotech Added to Russell 3000® Index
04 Jun 2019 9:01 pm GNW     XBiotech Inc. XBiotech Announces Closing of Public Offering of Common Shares
31 May 2019 1:47 pm GNW     XBiotech Inc. XBiotech Announces Pricing of Public Offering of Common Shares
30 May 2019 9:32 pm GNW     XBiotech Inc. XBiotech Announces Public Offering of Common Shares
23 May 2019 1:20 pm GNW     XBiotech Inc. XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa
02 May 2019 1:15 pm GNW     XBiotech Inc. XBiotech Announces Enrollment Completion, Positive Findings for Bermekimab in Pancreatic Cancer Study
05 Mar 2019 1:15 pm GNW     XBiotech Inc. Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics
01 Mar 2019 4:44 pm GNW     XBiotech Inc. Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting
29 Jan 2019 1:15 pm GNW     XBiotech Inc. Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting
28 Jan 2019 4:28 pm GNW     XBiotech Inc. Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting
23 Jan 2019 1:30 pm GNW     XBiotech Inc. Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain
13 Dec 2018 1:00 pm GNW     XBiotech Inc. XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study
12 Dec 2018 1:30 pm GNW     XBiotech Inc. XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease
03 Dec 2018 1:15 pm GNW     XBiotech Inc. XBiotech Announces Successful Completion of GMP Audit
31 Oct 2018 8:05 pm GNW     XBiotech Inc. XBiotech Highlights Third Quarter Developments for 2018
26 Oct 2018 1:15 pm GNW     XBiotech Inc. XBiotech Announces New Patents for Third Quarter 2018
24 Oct 2018 3:35 pm GNW     XBiotech Inc. XBiotech Announces Dismissal of Securities Class Action Suit
05 Oct 2018 1:00 pm GNW     XBiotech Inc. XBiotech Announces Enrollment Completion in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Atopic Dermatitis
26 Sep 2018 1:00 pm GNW     XBiotech Inc. XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases
24 Sep 2018 1:30 pm GNW     XBiotech Inc. XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa
20 Sep 2018 1:00 pm GNW     XBiotech Inc. XBiotech Announces Addition of Top Dermatologist and Researcher Dr. Alice Gottlieb to its Team
13 Sep 2018 1:00 pm GNW     XBiotech Inc. XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis
12 Sep 2018 1:00 pm GNW     XBiotech Inc. XBiotech Announces Addition of World Leading Cardiologist Dr. Peter Libby to its Scientific Advisory Board
27 Aug 2018 1:00 pm GNW     XBiotech Inc. XBiotech Announces Publication of Breakthrough Findings for Potential Role of Interleukin-1 alpha in Risk for Heart Attacks
10 Aug 2018 1:00 pm GNW     XBiotech Inc. XBiotech Highlights Quarterly Developments
22 May 2018 1:00 pm GNW     XBiotech, Inc XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis
16 Apr 2018 1:00 pm GNW     XBiotech, Inc XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology
02 Apr 2018 1:00 pm GNW     XBiotech, Inc XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer
26 Jan 2018 1:00 pm GNW     XBiotech, Inc XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
25 Jan 2018 1:00 pm GNW     XBiotech, Inc XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus
19 Jan 2018 1:00 pm GNW     XBiotech, Inc XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
04 Dec 2017 1:00 pm GNW     XBiotech, Inc XBiotech Announces Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study in The Journal of Investigative Dermatology
14 Nov 2017 12:30 pm GNW     XBiotech, Inc XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions
03 Nov 2017 4:16 pm GNW     XBiotech, Inc XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
18 Oct 2017 3:53 pm GNW     XBiotech, Inc XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
21 Sep 2017 1:00 pm GNW     XBiotech, Inc XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference
20 Sep 2017 1:00 pm GNW     XBiotech, Inc XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
07 Sep 2017 1:00 pm GNW     XBiotech, Inc XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t